Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immutep Ltd ADR (NQ: IMMP )

1.935 +0.095 (+5.16%)
Streaming Delayed Price Updated: 2:45 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 156,693
Open 1.920
Bid (Size) 1.930 (20)
Ask (Size) 1.940 (3)
Prev. Close 1.840
Today's Range 1.872 - 1.960
52wk Range 1.660 - 3.335
Shares Outstanding 748,152,935
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Immutep's Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer Trial
Immutep's INSIGHT-003 Phase 1 trial reports promising survival data for 1L NSCLC treatment using eftilagimod alpha, Keytruda, and chemotherapy. 
Via Benzinga
Immutep’s Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer
From Immutep Limited
Via GlobeNewswire

Performance

YTD
-17.66%
-17.66%
1 Month
-0.77%
-0.77%
3 Month
-19.37%
-19.37%
6 Month
-35.28%
-35.28%
1 Year
+2.93%
+2.93%

More News

Read More
Dow Jumps Over 200 Points; NY Empire State Manufacturing Index Increases In September
Via Benzinga
Topics Stocks
Exposures US Equities
Abbott, Integra LifeSciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Why ASP Isotopes Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
Australia Based Cancer Focused Immutep's Lead Cancer Drug Shows 'Meaningful Response' In Untreated Head & Neck Cancer, Stock Soars
Via Benzinga
Why Ericsson Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Via Benzinga
Immutep Touts Encouraging Data From Efti Triple Combination Therapy In Lung Cancer Setting
Via Benzinga
Maxim Group Maintains Buy Rating for Immutep: Here's What You Need To Know
Via Benzinga
Levi Strauss Posts Mixed Results, Joins Walgreens, AeroVironment And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Why Australian Cancer Biotech Firm Immutep Stock Is Soaring On Wednesday?
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B
From Immutep Limited
Via GlobeNewswire
Cancer Focused Immutep's Stock Soars On Tuesday - Here's Why
Via Benzinga
Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023
From Immutep Limited
Via GlobeNewswire
Immutep’s Efti in Combination with KEYTRUDA® Generates Excellent Overall Survival Benefit in Patients with Metastatic Non-Small Cell Lung Cancer
From Immutep Limited
Via GlobeNewswire
7 Stocks That Could Triple Your Money by 2024
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2023
Via Benzinga
3 Best Penny Stocks Under $3 to Buy in June
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Immutep Shares Spike As Cancer Tratement Shows Favorable Results In Phase 2 Trial
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.